|
Thomas' Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
KemSu sponsors seek renewed EU review as Meplyffa stalls, Lucid’s EsoGuard gains nationwide Medicare reimbursement, and Novo files etavopivat for approval.
The top 9 stories from Fri Nov 13, 2026 06:59 AM to Mon Nov 16, 2026 06:55 AM
Generated November 16, 2026 at 6:55 AM
|
|
|
#1 Summit's PD-1xVEGF rejected by FDA in lung cancer Published 2026-11-15 The FDA denied approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, preventing its U.S. launch after its 2024 availability in China. Covered by: biospace.com, insights.citeline.com, statnews.com, fiercebiotech.com, endpoints.news |
#2 US FDA, Sponsors Still Not Aligned On Streamlined Preclinical Programs Published 2026-11-13 The FDA is discussing how reviewers across divisions can apply a consistent approach to alternative preclinical development programs, while sponsors remain misaligned with the agency. Covered by: insights.citeline.com |
#3 Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval Published 2026-11-13 Novo submitted etavopivat for FDA and EMA approval, citing Phase 3 HIBISCUS trial efficacy and safety data in adolescents and adults with sickle cell disease. Covered by: prnewswire.com, prnewswire.com, insights.citeline.com |
#4 Rezolute gets an uplift from phase 3 tumor hyperinsulinism win ahead of FDA meeting Published 2026-11-13 Rezolute said its phase 3 trial of ersodetug for tumor hyperinsulinism met its primary endpoint, ahead of a potential FDA filing for another indication. Covered by: fiercebiotech.com |
#5 Faster Clinical Trials Act’s Bipartisan Backing Could Bolster US FDA User Fee Package Bid Published 2026-11-13 Bipartisan support for the Faster Clinical Trials Act could strengthen efforts to include it in the FDA user fee package; the bill proposes a hub-and-spoke clinical research system. Covered by: insights.citeline.com |
#6 PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results Published 2026-11-13 PAVmed reported that Lucid Diagnostics’ EsoGuard is now reimbursed by Medicare nationwide, while Veris Health began a 90-day animal study ahead of a planned early 2027 FDA submission. Covered by: prnewswire.com |
#7 Deaths, failed trials and other recent setbacks in the autoimmune space Published 2026-11-16 Novartis, Bristol Myers Squibb, argenx and other drugmakers have faced autoimmune-program setbacks, including discontinued assets, strategic pauses and safety concerns. Covered by: biospace.com |
#8 Pink Sheet Podcast: US FDA’s CNPV Program Ends, Commissioner Nominee’s Day Of Reckoning Arrives Published 2026-11-13 The Senate HELP Committee is expected to decide whether to advance Heidi Overton’s nomination as FDA commissioner, as the agency’s CNPV program ends. Covered by: insights.citeline.com |
#9 KemSu Sponsors Plot EU Resubmission As Meplyffa Hits Another Roadblock Published 2026-11-13 KemSu’s sponsors are seeking to overturn EU decisions through the re-examination procedure, as Meplyffa faces another regulatory setback. Covered by: insights.citeline.com |